ReviewAdvances in experimental medicine and biology2026
Cell-Free DNA (cfDNA), Its Applications in Cancer Diagnosis and Monitoring, and Its Potential Role in Regulating Cancer Metabolism.
Review in Advances in experimental medicine and biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cell-free DNA (cfDNA) has emerged as a valuable biomarker in cancer diagnosis, monitoring, and prognosis. cfDNA refers to small fragments of DNA that are released into the bloodstream from tumor cells, normal cells, or dying cells within the body. In the context of cancer, circulating tumor DNA (ctDNA), a subset of cfDNA, contains tumor-specific genetic mutations, epigenetic alterations, and structural variations that can be used to detect the presence of cancer, track disease progression, and assess therapeutic response. Beyond its diagnostic potential, cfDNA plays a significant role in the regulation of cancer cell features and potentially cancer metabolism. Recent studies suggest that cfDNA is not merely a passive byproduct of cellular turnover but may actively influence tumor microenvironments, inflammation, and metabolic pathways, thereby impacting cancer progression. This review explores the clinical utility of cfDNA in cancer, its emerging role in metabolic regulation, and its potential to transform personalized cancer therapy by providing non-invasive, real-time insights into tumor dynamics.
Indexed as
Identifiers
42435174What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.